Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Svetlana Vasilievna Chulkova has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiple myeloma: plasma cell immunophenotype and monitoring of minimal residual disease after induction therapy and autologous hematopoietic stem cell transplantation

    by Natalya A. Kupriyshina, Купрышина Н. А., Svetlana V. Chulkova, Чулкова Светлана Васильевна, Anastasiya A. Semenova, Семенова А. А., Olga P. Kolbatskaya, Колбацкая О. П., Gayane S. Tumyan, Тумян Г. С., et al.

    Background. Minimal residual disease (MRD) is the presence of a tumor clone in the bone marrow that can prevent remission during treatment. The immunophenotype of MM cells may be different, so it is necessary to understand the spectrum of markers that allow differentiating abnormal plasma cells (PCs). Monitoring MRD can influence the choice of patient management tactics. Aim. Analysis of the immunophenotype of myeloma cells and assessment of the frequency of MRD during treatment. Materials and methods. The study included 56 MM patients, the average age was 55 years. Induction chemotherapy was carried out according to the VRD scheme (including lenalidomide, bortezomib, and dexamethasone), autologous hematopoietic stem cell transplantation (auto-HSCT). The MOB status was assessed by multicolored flow cytometry using a Becton Dickinson FACSCanto II cytofluorimeter (Becton Diskinson, USA), Kaluza Analysis v. 2.1 (Beckman Coulter, Inc., USA). Monoclonal antibodies of clusters of differentiation (CD) were used: CD45, CD19, CD27, CD56, CD28, CD38, CD117, CD19, CD81, immunoglobulin light chains κ / λ, nuclear dye 7-aminoactinomycin D (Becton Diskinson, USA). Results. The most common MM immunophenotype was aberrant in the absence of CD19 and CD27, reduced expression of CD38, and abnormal presence of CD56 was noted. There is aberrancy in CD27 / CD117 / CD81. Most often, the immunophenotype of PCs corresponded to CD19–CD45–CD56+, noted in 46.4 % of cases. The frequency of MRD negativity after induction therapy is 35.7 %, after auto-HSCT – 56.7 %. A 1.3-fold decrease in the number of PCs in the bone marrow after auto-HSCT was established. Conversion after auto-HSCT of MRD positive cases (before transplantation of PCs more than 0.01 %, but less than 0.1 %) was detected in 53 % of patients. Conclusion. The MRD status in MM is assessed based on the aberrant expression of the main and additional plasma cell markers. At the stage of induction therapy and after auto-HSCT, the MRD status differs and there is a conversion of MRD-positive cases to negative ones. Monitoring MRD can be useful for choosing the tactics of managing patients with MM.

  • Open Access

    ANALYSIS OF PHYTOCOMPOSITION FOR PREVENTIVE ONCOLOGY BY GAS CHROMATOGRAPHY – MASS SPECTROMETRY

    by Andrey Anatolyevich Aksyonov, Evgeny Valerianovich Bocharov, Regina Vasilyevna Karpova, Boris Tsalerievich Zaychik, Olga Petrovna Sheychenko, Ilya Vladimirovich Kazeev, Svetlana Vasilievna Chulkova, Alexander Evgenyevich Barmashov, Valerian Grigoryevich Kucheryanu, Natalia Valeryevna Pyatigorskaya, et al.

    Preventive oncology approaches are aimed, among other things, at averting, slowing, or suppressing the development of malignant tumors. Numerous preventive drugs are derived from plant-based biologically active compounds. The diversity of their structures provides a broad spectrum of antitumor activity. Complex herbal formula are highly effective and safe due to their multi-target effects on various regulatory mechanisms as well as relatively low toxicity. The article outlines the findings from the initial phase of a chemical investigation into a novel pharmaceutical composition phytoladaptogen utilizing gas chromatography-mass spectrometry. Analysis was conducted with the employment of Shimadzu GC 2010 chromatograph with a GCMS-QP 2010 mass spectrometric detector. Scanning mode is total ion current (TIC) measurement. Based on retention times, a library of mass spectra and literature data a total of 42 compounds were identified. Fourteen key compounds were: beta-myrcene; alpha-, beta-pinenes; 1,8-cineole; sabinene; abietic acid; phloroglucinol; α-linolenic, palmitic, stearic, oleic, and linoleic acids; naphthalene and fluorene. The results can serve as a basis for developing the optimal composition of a herbal formula intended for the creation of a new oncoprotective agent. The presented approach can be applied also to the quality control of multicomponent mixtures.

  • Lymphoid populations and tumor disseminated cells in the bone marrow in early breast cancer

    by Svetlana V. Chulkova, Elena N. Sholokhova, Olga P. Kolbatskaya, Irina A. Gladilina, Angelina V. Egorova, Ivan S. Stilidi, Tatiana N. Zabotina

    Background. The study of lymphoid populations is a necessary step for understanding the interaction between the tumor and the immune system, as well as for a detailed analysis of the persistence of tumor cells in the bone marrow of patients with breast cancer. Lymphoid populations of the bone marrow can serve as a potential point of application for immunotherapy. Aim. To study the composition of lymphoid populations and assess the relationship with disseminated tumor cells in the bone marrow of patients with operable breast cancer Materials and methods. The study included 65 bone marrow samples obtained by sternal puncture in patients with breast cancer. Ductal adenocarcinoma stage T1 / T2, N0 status prevailed. Luminal A was detected in 51.3 %, luminal B 10.3 %, Erb-B2 overexpressing subtype was established in 15.4 % and triple-negative subtype in 6.4 %. T cells (CD3), B cells (CD19), NK cells (CD56+CD3– ), minor populations of TCRγδ and TCRαβ lymphocytes, CD4+CD25+ T cells, subpopulations of CD10+, CD38+, CD5+ B cells were studied. CD45+EpCAM+ cells among myelokaryocytes of a bone marrow sample were assessed. An immunological study of bone marrow using monoclonal antibodies (Becton Diskinson, USA) was performed on a FACS Canto II flow cytometer. The results were analyzed using the Kaluza Analysis v.2.1 program. Results. A relationship was established between CD19+CD10+ cells and the morphological type of breast cancer: their increased content was noted in ductal adenocarcinoma (p ≤0.05). There was a relationship between lymphogenous metastasis and the level of CD5+CD38+ cells (p ≤0.05). In high-grade cancer, there was an increase in the proportion of CD4+CD25+ cells, estrogen-positive tumors were distinguished by the predominance of NK cells in the bone marrow (p ≤0.05). T-lymphoid populations are associated with the presence of disseminated tumor cells in the bone marrow. An increase in the proportion of CD4+CD25+ with a decrease in the number of CD3+HLA-DR+ and B-cells was noted (p = 0.03). Conclusion. Lymphoid populations of the bone marrow are associated with the morphological characteristics of breast cancer. In metastatic bone marrow lesions, the proportion of T-cell lymphoid populations changes and the number of B-cells decreases.

  • CLINICAL SIGNIFICANCE OF METHYLATION OF LNCRNA GENES GAS5, ZEB1-AS1 IN TUMORS OF PATIENTS WITH BREAST CANCER

    by A. Osipova, D. Ryabchikov, S. Chulkova, V. Loginov, A. Burdennyy, N. Kushlinskii

    Introduction. Long non-coding RNAs (LncRNAs) are transcripts whose role in carcinogenesis is poorly understood. LncRNA expression determines the biological properties of a cell, including invasive potential and ability to migrate. Methylation status changes lncRNA functions and can be a marker of tumor prognosis. The aim of the work is study the methylation frequency of the LncRNA genes GAS5, ZEB1-AS1 in breast cancer and to evaluate the clinical signifi-cance. Material and methods. 140 patients with breast cancer were examined, mainly with T1 – (38.7%) and T2 – (55.6%) stages, N0 status – (54.0%), N1 status – (37.9%). Luminal type of breast cancer – 80% (n = 113), non-luminal – 20% (n = 27). Morphologically: invasive ductal carcinoma (77.1%), G2 differentiation (62.9%) were predominantly detected. Methylation of CpG regions of promoter regions of the GAS5, ZEB1-AS1 lncRNAs genes in paired tumor and histologically unaffected breast tissue samples was studied using the methyl-specific PCR method. The T100 amplifier (Bio-Rad, USA) and Lasergene 17.1 primers from DNASTAR (USA) were used in the work. Statistical data processing was performed in the SPSS, v. 23 program. Results. The frequency of methylation of the GAS5, ZEB1-AS1 genes in the tumor is higher than in histologically unaffected breast tissue. Gene meth-ylation is associated with age, R = 0.43 (GAS5) and R = 0.26 (ZEB1-AS1), and increases the stage tumor process. A correlation was established be-tween GAS5 gene methylation and the T index (R = 0.21, p < 0.05), N status (R = 0.31, p < 0.05). There is an inverse correlation with the biological subtype of luminal cancer (R = –0.29, p < 0.05). The absence of methylation of the GAS5 and ZEB1-AS1 genes is associated with a decrease in 5-year overall survival and 10-year progression-free survival in breast cancer. Conclusions. In breast cancer, methylation of the lncRNAs GAS5, ZEB1-AS1 genes in the tumor exceeds that in the unchanged breast tissue. The methylation status of the genes GAS5, ZEB1-AS1 is associated with the stage, tumor size, regional metastasis, and does not affect the long-term treatment results.

  • Open Access

    Detection of minimal residual disease after induction chemotherapy and autologous HSCT and its clinical significance in multiple myeloma

    by Svetlana V. Chulkova, Natalia A. Kupriyshina, Anastasiya A. Semenova, Olga P. Kolbatskaya, Gayane S. Tumyan

    Background. Minimal residual disease (MRD) study is a necessary step for detailed analysis of tumor clone persistence in bone marrow of patients with multiple myeloma (MM), which is important for assessing the depth of remission during treatment. MRD assessment can be useful for building a prognosis of MM and choosing patient management tactics.Aim. To assess the frequency of MRD and its prognostic significance in patients with MM during treatment.Materials and methods. The study included 56 patients with MM, the average age of which was 54.9 ± 1.3 years.All patients received induction chemotherapy, which was carried out according to the Vrd regimen. After induction therapy and 100 days after autologous hematopoietic stem cell transplantation (auto-HSCT), MRD status was assessed. MRD status was assessed by multicolor flow cytometry (FACSCanto II, Kaluza Analysis v2.1 software, USA). Monoclonal antibodies: CD45, CD19, CD27, CD56, CD28, CD38, CD117, CD19, CD81, immunoglobulin light chains kapa / lambda, 7ADD (Becton Diсkinson, USA).Results. The frequency of MRD-negative status after induction therapy was 35.7 %, after auto-HSCT – 56.7 %.A decrease in the number of abnormal plasma cells (PC) in the bone marrow by 1.3 times was noted compared to the induction therapy stage. Conversion of MRD-positive cases was established during treatment. In the group with the PC content in the bone marrow after induction therapy more than 0.01 %, but less than 0.1 %, the MRD status changed after auto-HSCT and became negative in 53 % of patients. In the presence of PC more than 0.01 % after induction, the progression rate increased more than 2-fold and was 50.0 % (p 0.05). The average number of PCs in patients without disease progression detected after auto-HSCT was significantly lower: 0.02 % versus 0.31 %, p 0.05.Conclusion. The frequency of MRD-negative status at the stage of induction therapy and after auto-HSCT differs, so several control points are important. After auto-HSCT, there is a conversion of MRD-positive cases to negative ones. Progression of MM was observed more often with MRD-positive status. Monitoring of MRD can help in selecting candidates for joining maintenance treatment of MM.

  • Open Access

    Correlation of CD71 transferrin receptor expression with ICAM-1 adhesion molecule expression by breast cancer cells

    by S. V. Chulkova, E. N. Sholokhova, I. V. Poddubnaya, I. S. Stylidi

    Background. Transferrin receptor 1 (CD71) plays a vital role in regulating cellular iron import. Cancer cells aberrantly express transferrin receptor 1 (CD71). Expression of CD71 receptors influences many aspects of tumorigenesis. Studying the expression of CD71 in breast cancer cells may reveal the peculiarities of tumor biology in order to select a priority type of drug treatment.Aim. Study the CD71 phenotype of breast cancer cells and evaluate its relationship with adhesion molecules.Materials and methods. We studied tumor samples obtained from breast cancer patients who were treated at the N.N. Blokhin National Medical Research Center of Oncology. On cryostat sections of the tumor, the CD71 phenotype (transfecrrin receptors), CD54 phenotype (intercellular adhesion molecule ICAM-1), and CD29 phenotype (common β-subunit of VLA antigens) were assessed using immunofluorescence. A ZEISS luminescent microscope (AXIOSKOP, Germany) was used. The assessment was performed using a semi-quantitative method: two types of positive reaction were identified according to Hammerling (mosaic and monomomorphic). Using contingency tables (Fisher’s exact test or Pearson’s χ2 test), the correlation between the expression of transferrin receptor molecules and adhesion molecules was studied.Results. The phenotype of breast cancer corresponded to CD71 monomorphic, which was noted in 64.4 % of samples (n = 61). Adhesion molecules were expressed in the majority of samples. β-1 CD29 integrins are presented monomorphically in 51.6 %. Expressing tumor adhesion molecules ICAM-1 in 37 cases showed a monomorphic type of receptor expression, and in 17 cases – mosaic. The expression of CD71 molecules was significantly associated with the expression of CD54 adhesion receptors. This was that CD71 positive tumors more often demonstrated expression of the CD54 receptor and this was expressed in a monomorphic type of reaction, which was 33 % versus 10.5 % (0.293, p = 0.008). With the mosaic CD71 phenotype, the proportion of tumors mosaically expressing CD29 β1-integrin molecules was 80.0 %, while with the CD71 monomorphic phenotype it was 33.3 %, in most cases (52.4 %) tumors with monomorphic expression of CD29 were observed (versus 20.0 % for mosaic phenotype).Conclusion. Breast cancer cells are characterized by an overexpression phenotype of CD71, which is correlated with the expression of CD54 adhesion molecule (ICAM-1). The monomorphic expression of β1-integrin molecules, which occurs in CD71 positive tumors (with a monomorphic type of reaction), indicates that these cells have a higher metastatic potential.

  • Open Access

    Impact of the tumor microenvironment of breast cancer on prognosis and treatment

    by K. S. Titov, S. V. Chulkova, H. M. Zapirov, Z. V. Lorie, M. V. Kiselevskiy

    According to world Health Organization, breast cancer (BC) ranks first among cancer diseases in women in many developed countries of the world and in the Russian Federation. Over the past 20 years, the incidence of breast cancer in the world has increased and continues to increase. This phenomenon dictates the need for a more in-depth molecular biological, genetic and immunological study of the mechanisms of development and progression of this heterogeneous malignant tumor.Recently, there has been increasing interest in the world not on lyin the direct causes of tumor development, but also in factors contributing to its progression, such as the cellular microenvironment of the tumor, the composition of which has a great influence on cancer development, treatment and prognosis. In the cellular microenvironment of the tumor, mononuclear cells are assessed, the proportion of which determines the severity and direction of the immuneresponse. Their importance for choosing the priority type of drug therapy and assessing its effectiveness is shown. The article provide scurrent data on subpopulations of T cells (CD8+, CD4+), B cells (CD20+), and natural killer. Their role in the development and progression of breast cancer is discussed depending on their phenotype. Modern research pays attention to a minor subpopulation of T lymphocytes – TCR-Vδ1+ cells. This subpopulation is represented predominantly in tumor tissue and has an immunosuppressive effect on T-effectors. At the present stage, inflammatory cells – macrophages and neutrophils – are of no less interest. Their role in tumor progression is widely debated. It is known that the differentiation of macrophages into M1 or M2 phenotypes is determined by the tumor microenvironment. The predominance of macrophages with protumor activity promotes tumor progression and cancer metastasis. Additionally, macrophages can stimulate the migration of neutrophils, which, in turn, support the metastasis of breast cancer through the production of matrix metalloproteinases. Matrix metalloproteinase 9 has been reported to promote the formation of vascular endothelial growth factor, which explains the protumor properties of neutrophils. In the context of growing tumor immunotherapy, assessment of tumor microenvironmental factors is promising both in relation to monitoring the effectiveness of breast cancer therapy and in relation to the search for potential therapeutic targets. The review systematizes and summarizes information on this issue to date.

  • Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer

    by S.V. Chulkova, E.N. Sholokhova, I.V. Poddubnaya, I.A. Gladilina, A.V. Egorova, I.S. Stilidi

    Cancer cells can aberrantly express various markers, including transferrin receptor 1 (CD71) and β1-integrin molecules. Their role in invasion, migration and metastasis has been demonstrated. Determination of their expression in breast cancer (BC) may be an important point to characterize the clinical course of the tumor and prognosis of the disease. Objective. To study of transferrin receptor 1 (CD71) expression by primary breast cancer cells in correlation with tumor cell phenotype. Material and methods. Determination of BC phenotype: immunohistochemical staining method (immunofluorescence). Antibodies to ER (estrogen receptors), KL-1 (pancytokeratin), CD71 (transferrin receptor), CD29 (β1-integrins). CD45, CD3, CD4, CD8, CD20 infiltration was also evaluated. ZEISS microscope (AXIOSKOP; Germany), method of G.J. Hammerling et al. Statistical processing: IBM-SPSS Statistics v.21. Results. 63% of BC cases had CD71+ phenotype. CD71-mosaic tumors were observed in 14.4%. β1-integrin expression was monomorphic in 51.6% of cases and mosaic in 38.7%. 85% of ER-positive tumors were CD71-positive with a monomorphic type of reaction; p=0.014. Among ER-negative tumors, CD71-negative reactions were 2-fold more frequent and the monomorphic type was less frequent. ER-positive tumors were CD29-positive in 73%; p=0.031. 45.5% of ER+ tumors were CD29-monomorphic. Among ER-negative tumors, the frequency of CD29-monomorphic tumors was 55%. Significant infiltration by CD3+ cells was predominant in CD71-positive tumors; p=0.016. In the CD29-monomorphic phenotype, CD45+ infiltration was 31.3%, and in the mosaic phenotype, 67.1%. Conclusion. BC aberrantly expresses transferrin receptors, β1-integrins. CD71 expression is associated with ER expression. ER-positive tumors are often monomorphic for CD71. Prominent CD3+ infiltration was present in CD71+ tumors. Expression of β1-integrins correlated with ER+ status and weak immune infiltration.

  • Open Access

    Second line chemotherapy for advanced biliary cancer: FOLFOX versus FOLFIRI: Analysis of retrospective and prospective data

    by Ilya V. Savchenko, Ivan S. Stilidi, Irina A. Dzhanyan, Elena Yu. Antonova, Alexander N. Polyakov, Angelina V. Egorova, Svetlana V. Chulkova, Valeriy V. Breder, Поляков Александр Николаевич

    Aim. To evaluate the efficacy and toxicity of second-line polychemotherapy according to FOLFOX or FOLFIRI regimen in patients with biliary tract tumours after progression during first-line chemotherapy (CT). Materials and methods. The study is based on the analysis of retrospective and prospective data on the examination and treatment of 94 patients with biliary cancer of grades T1-4N0-2M0-1 followed-up and treated at the N.N. Blokhin National Medical Research Center of Oncology from 2015 to 2023. All patients were divided into 2 groups: Group 1 (FOLFOX, n=47) and Group 2 (FOLFIRI, n=47). In Group 1, patients received the recommended FOLFOX second-line CT regimen. Patients in Group 2 received FOLFIRI regimen. The endpoints were overall survival (OS) and incidence of grade 3-4 adverse events. Results. The study included 94 patients. In the FOLFOX group, the median OS was 13.0 months (1-year OS was 57.8±7.4%); for the FOLFIRI group, the median OS was 12.3 months (1-year OS was 54.4±7.3%). The toxicity profiles of FOLFOX and FOLFIRI were acceptable and consistent with those reported for the regimens. According to the grade 3–4 toxicity data, diarrhea was significantly more common in the FOLFIRI group (p=0.014), and neurotoxicity was more common in the FOLFOX group (p=0.006). During the second-line CT, the frequency of grade 1–4 toxicities in the groups did not differ: 18 (38.3%) events in the FOLFOX group and 19 (40.0%) events in the FOLFIRI group. Conclusion. Our results of evaluating the efficacy and toxicity of the second-line polychemotherapy regimens show that the FOLFOX and FOLFIRI CT regimens have equal efficacy in patients with advanced biliary tract cancer with a good performance according to the ECOG scale, who previously received the first-line therapy with a combination of gemcitabine with a platinum agent (cisplatin or oxaliplatin); also, our data demonstrate similar toxicity profiles of these regimens.


  • Open Access

    Cryosurgery for Basal Cell Skin Cancer of the Head: 15 Years of Experience

    by Ilya Pustinsky, Anton Dvornikov, Ekaterina Kiva, Svetlana Chulkova, Angelina Egorova, Irina Gladilina, Sergey Peterson, Nataly Lepkova, Natalya Grishchenko, Zamira Galaeva, et al.

    The clinical relevance of head and neck (H&N) tumors is related to the potential disfiguration of anatomical structures (by the tumor or surgical intervention), defining patients’ individual features and emotional expression, loss or restraint of vital structures functions, and untoward socio-economic sequelae. This study is aimed to improve clinical outcomes of cryosurgery in patients with H&N basal cell skin cancer by refining the indications for cryosurgical treatment. In this study, cryosurgery was used in 234 patients with different stages of cutaneous basal cell carcinoma (BCC) of the head, including 101 patients with T1 tumors, 86—with T2, 5—T3, and 42 patients with tumors relapsing after failure of preceding various treatment modalities. Post-cryosurgery recurrence rate in patients with stage I BCC was 2.7%, with stage II tumors—5.6% and 34.9%—in patients with recurred tumors. Re-recurrence after cryoablation of recurrent tumors correlated with the tumor baseline size. The best aesthetic and long-term clinical results were documented in patients with lesions <1 cm in size with clear boundaries. Thus, cryosurgery is the method of choice for the majority of stage I basal cell carcinomas of the head. For patients with advanced and recurrent skin cancer, cryosurgery is relevant in rare cases selected according to refined indications.